Novel heterocycle-substituted pyrimidine derivatives exhibiting inhibitory effect on cancer cell growth and pharmaceutical compositions containing the same
Novel heterocyclic-substituted pyrimidine derivatives with N-Alkyl alkylsulfonamide groups address drug resistance in ALK-positive non-small cell lung cancer by inhibiting ALK and EGFR mutations, enhancing treatment efficacy against cancer cells.
Patent Information
- Application Number
- JP2024529235
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-12-08
- Filing Date
- 2022-12-09
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for ALK-positive non-small cell lung cancer face challenges due to drug resistance mechanisms, particularly mutations that inhibit the binding force between kinase proteins and drugs, leading to reduced efficacy, necessitating the development of compounds that effectively suppress ALK-mutated or EGFR-mutated cancer cells.
Development of novel heterocyclic-substituted pyrimidine derivatives containing a N-Alkyl alkylsulfonamide functional group that inhibit the enzymatic activity of ALK and EGFR mutations, offering a pharmaceutical composition for treating ALK overexpression, ALK mutations, or EGFR mutations in cancer cells.
The novel pyrimidine derivatives demonstrate superior enzyme inhibitory activity against ALK and EGFR mutations, effectively inhibiting cancer cell growth and overcoming resistance mechanisms, with potential applications in treating various cancers including non-small cell lung cancer.
Smart Images

Figure 2024544576000001 
Figure 2024544576000002 
Figure 2024544576000003
Abstract
Description
[Technical field]
[0001] This application claims the benefit of priority based on Korean Patent Application No. 10-2021-0175542 filed December 9, 2021 and Korean Patent Application No. 10-2022-0170783 filed December 8, 2022, and all contents disclosed in the documents of said Korean patent applications are incorporated herein by reference.
[0002] The present invention relates to novel heterocycle-substituted pyrimidine derivatives that effectively inhibit the growth of various cancer cells, and pharmaceutical compositions containing the same. [Background technology]
[0003] Non-small cell lung cancer (NSCLC), which occurs due to various causes, is a disease with a very high prevalence and mortality rate of cancer-related diseases. NSCLC is mainly caused by the mutation or overexpression of tyrosine kinase, and anticancer drugs developed to date mainly aim to inhibit the activity of cancer-inducing enzymes associated with such specific mutations.
[0004] Non-small cell lung cancer is caused by the expression, fusion, and rearrangement of various tumor genes, including ALK, KRAS, and ROS1, along with mutations in EGFR, known as the epidermal growth factor receptor. ALK (Anaplastic Lymphoma Kinase) gene abnormalities (EML4-ALK transfusion) are observed in approximately 12% of non-small cell lung cancer patients, and ALK-positive non-small cell lung cancer is caused by the fusion of the ALK and EML4 genes. The fusion of these two genes is known to accelerate the growth rate of cells caused by the ALK gene, and rapidly transforms cells that receive this signal into cancer cells (tumor cell transformation).
[0005] A typical example is crizotinib, a first-line treatment for ALK-positive cancer. It was approved by the US FDA in 2011 as a multi-targeted anti-cancer drug and is used to treat metastatic and ALK-positive non-small cell lung cancer by inhibiting the activity of c-MET, ALK, ROS1, etc.
[0006] As with other anticancer drugs, the use of crizotinib inevitably leads to the development of resistance, mainly due to secondary mutations in the ALK kinase domain (approximately 30%), amplification of ALK fusion mutations, and activation of bypass signaling pathways.
[0007] Therefore, crizotinib-resistant patients are receiving ceritinib, alectinib, and brigatinib as second-line treatments, and second-line treatment-resistant patients are receiving lorlatinib as a third-line treatment.
[0008] In all ALK-positive non-small cell lung cancers induced by ALK fusion, the main resistance mechanism is known to be mutations that suppress the binding strength of the kinase protein to drugs, and it has been reported that such mutations affect downstream signaling within the cell, preventing the drug from acting any further.
[0009] Although the development of ALK fusion protein inhibitors has been ongoing, the development of inhibitors that can solve the resistance problem is relatively slow. Therefore, there is a need to develop drugs that can effectively inhibit the growth of ALK mutant cancer cells, which is the main drug resistance mechanism. [Prior art documents] [Non-patent literature]
[0010] Nature Reviews Clinical Oncology(2018)15 694-708. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next - generation TKIs PLoS ONE(2020)15(2). ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis. Oncotarget(2016)7(1) 1066-75. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Summary of the Invention [Problem to be solved by the invention]
[0011] The present inventors have endeavored to develop novel compounds that effectively inhibit ALK-mutated or EGFR-mutated cancers or proliferative diseases, and as a result have discovered novel heterocyclic-substituted pyrimidine derivatives containing an N-alkyl alkylsulfonamide functional group that are effective in the treatment of cancer.
[0012] The present invention aims to provide a novel heterocyclic-substituted pyrimidine derivative containing an N-alkyl alkylsulfonamide functional group, which is effective in treating cancer or proliferative diseases.
[0013] Another object of the present invention is to provide a pharmaceutical composition for treating ALK-overexpressing, ALK-mutated, or EGFR-mutated cancer or proliferative disease, comprising the novel heterocyclic-substituted pyrimidine derivative having an N-alkyl alkylsulfonamide functional group.
[0014] Another object of the present invention is to provide a pharmaceutical composition for treating ALK-mutated or EGFR-mutated non-small cell lung cancer. [Means for solving the problem]
[0015] In order to achieve the above object, the present invention provides The present invention provides a compound represented by the following formula 1, or a pharma- ceutically acceptable salt thereof: [ka]
[0016] In the above Chemical Formula 1, R1 is a C1-C4 alkyl group, a C3-C6 cycloalkyl group, CF3, or NR 8 R 9 where R 8 and R 9 are each independently hydrogen or a C1-C4 alkyl group, R2 is hydrogen, a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or -NR 10 R 11 and R 10 and R 11 are each independently hydrogen or a C1-C4 alkyl group, R3 is hydrogen or a halogen group; R4 is hydrogen, halogen, OH, CN, CF3, C1-C4 alkoxy, or C1-C4 alkyl group; R5 is a C1-C4 alkoxy group, a C3-C6 cycloalkoxy group, a C1-C4 alkoxy group substituted with CF3, a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or a C3-C6 heterocycloalkyl group, wherein the heterocycloalkyl group contains 1 to 3 heteroatoms selected from N, O, and S; R6 is hydrogen, a halogen group, a C1-C4 alkyl group, or a C3-C6 cycloalkyl group; R 1a , R 1b , R 2a and R 2b are each independently hydrogen, a C1-C4 alkyl group, or halogen; R7 is hydrogen, a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or a C3-C8 heterocycloalkyl group, wherein the heterocycle contains 1 to 3 heteroatoms selected from N, O and S.
[0017] The compound of formula 1 above, or a pharma- ceutically acceptable salt thereof, may be used in the treatment of cancer or a hyperproliferative disease.
[0018] The present invention also provides a method for producing a semiconductor device comprising the steps of: The present invention provides a pharmaceutical composition for treating cancer or a hyperproliferative disease, comprising as an active ingredient the compound represented by the above formula 1 or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.
[0019] The cancer or hyperproliferative disease may be caused by ALK overexpression, ALK mutations, or EGFR mutations.
[0020] The present invention also provides a method for treating an animal suffering from cancer or a hyperproliferative disease, which comprises administering to the animal an effective amount of the compound represented by Chemical Formula 1 above or a pharma- ceutically acceptable salt thereof.
[0021] The cancer or hyperproliferative disease may be caused by ALK overexpression, ALK mutations, or EGFR mutations. Effect of the Invention
[0022] The novel heterocyclic substituted pyrimidine derivative compound or a pharma- ceutically acceptable salt thereof of the present invention effectively inhibits the enzymatic activity of ALK, G120R ALK, L1196M ALK, and the enzymatic activity of del19 / L858R / T790M EGFR, del19 / T790M / C797S.
[0023] In addition, the novel heterocyclic substituted pyrimidine derivative compound or its pharma- ceutical acceptable salt of the present invention can effectively inhibit the growth of ALK overexpression, ALK mutation, or EGFR mutation cancer cells, and can therefore be useful in the treatment of ALK overexpression, ALK mutation, or EGFR mutation cancer or proliferative disease. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] The present invention will be described in detail below with reference to examples. However, these are merely examples and do not limit the present invention, and the present invention is defined only by the scope of the claims below. Furthermore, detailed descriptions of configurations that are essential for implementing the present invention but that can be easily implemented by those skilled in the art using known techniques will be omitted.
[0025] Hereinafter, unless otherwise specified, the term "compound of the present invention" or "compound of Chemical Formula 1" is used as a concept including both the compound itself and a salt thereof.
[0026] As used herein, the term "C1-C4 alkyl group" refers to straight and branched chain hydrocarbon groups having the specified number of carbon atoms. The alkyl group may be, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, etc.
[0027] In this specification, the term "C3-C6 cycloalkyl group" may be selected from a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group.
[0028] In this specification, the term "C1-C4 alkoxy group" may be linear or branched. Specifically, it may be selected from methoxy, ethoxy, n-propoxy, or isopropoxy.
[0029] As used herein, the term "alkylsulfonyl" refers to alkyl-S(O2)-, where alkyl is defined above.
[0030] The term "halogen" as used herein may be selected from F, Cl, Br, or I.
[0031] The present invention relates to a compound represented by the following formula 1 or a pharma- ceutically acceptable salt thereof. [ka]
[0032] In the above Chemical Formula 1, R1 is a C1-C4 alkyl group, a C3-C6 cycloalkyl group, CF3, or -NR 8 R 9 where R 8 and R 9 are each independently hydrogen or a C1-C4 alkyl group, R2 is hydrogen, a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or -NR 10 R 11 where R 10 and R 11 are each independently hydrogen or a C1-C4 alkyl group, R3 is hydrogen or a halogen group; R4 is hydrogen, halogen, OH, CN, CF3, C1-C4 alkoxy, or C1-C4 alkyl group; R5 is a C1-C4 alkoxy group, a C3-C6 cycloalkoxy group, a C1-C4 alkoxy group substituted with CF3, a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or a C3-C6 heterocycloalkyl group, wherein the heterocycloalkyl group contains 1 to 3 heteroatoms selected from N, O, and S; R6 is hydrogen, a halogen group, a C1-C4 alkyl group, or a C3-C6 cycloalkyl group; R 1a , R 1b , R 2a and R 2b are each independently hydrogen, a C1-C4 alkyl group, or halogen; R7 is hydrogen, a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or a C3-C8 heterocycloalkyl group, wherein the heterocycle contains 1 to 3 heteroatoms selected from N, O and S.
[0033] In the above formula 1, preferably, R1 is a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or -NR 8 R 9 where R 8 and R 9 are each independently hydrogen or a C1-C4 alkyl group, R2 is hydrogen, a C1-C4 alkyl group, or a C3-C6 cycloalkyl group; R3 is hydrogen or a halogen group; R4 is hydrogen, halogen, OH, CN, or CF3; R5 is a C1-C4 alkoxy group, a C3-C6 cycloalkoxy group, or a C1-C4 alkoxy group substituted with CF3; R6 is hydrogen, a C1-C4 alkyl group, or a C3-C6 cycloalkyl group; R 1a , R 1b , R 2a and R 2b is hydrogen, R7 is a C3-C6 cycloalkyl group or a C3-C8 heterocycloalkyl group, where the heterocycle may contain 1 to 3 heteroatoms selected from N, O and S.
[0034] In the above formula 1, more preferably, R1 is a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or -NH2; R2 is hydrogen, a C1-C4 alkyl group, or a C3-C6 cycloalkyl group; R3 is hydrogen; R4 is a halogen; R5 is a C1-C4 alkoxy group, a C3-C6 cycloalkoxy group, or a C1-C4 alkoxy group substituted with CF3; R6 is a C1-C4 alkyl group; R 1a , R 1b , R 2a and R 2b is hydrogen, R7 is a C5-C8 heterocycloalkyl group, where the heterocycle may contain one heteroatom selected from O and S.
[0035] Specifically, the compound of Chemical Formula 1 may include the following compounds. N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylcyclopropanesulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylpropane-2-sulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-cyclopropylmethanesulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-isopropylmethanesulfonamide, N-(2-((5-chloro-2-((5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-(2,2,2-trifluoroethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylsulfonamide.
[0036] The compound of the present invention shown in Chemical formula 1 effectively inhibits the enzyme activity of ALK, G120R ALK, L1196M ALK, and the enzyme activity of del19 / L858R / T790M EGFR, del19 / T790M / C797S.In addition, the compound of the present invention shown in Chemical formula 1 has a very excellent enzyme inhibitory activity compared to crizotinib.
[0037] Therefore, the compound of the present invention shown in Chemical formula 1 or its pharma- ceutically acceptable salt may be used as a drug for treating or preventing cancer or hyperproliferative disease. The cancer or hyperproliferative disease may be a disease caused by ALK overexpression or ALK mutation, and a disease caused by EGFR mutation.
[0038] The cancer may be selected from the group consisting of liver cancer, gastric cancer, pancreatic cancer, colon cancer, leukemia, myeloproliferative / myelodysplastic disease, dermatofibrosarcoma, breast cancer, lung cancer, thyroid cancer, prostate cancer, ovarian cancer, brain tumor, osteosarcoma, and head and neck cancer, etc. The lung cancer may be small cell lung cancer or non-small cell lung cancer.
[0039] The cancer may also be non-small cell lung cancer caused by ALK overexpression, ALK mutation, or EGFR mutation, and the cancer may be a secondary cancer that has metastasized to other organs from the various types of cancer.
[0040] The compound represented by Chemical formula 1 according to the present invention may be used in the form of a pharma- ceutically acceptable salt derived from an inorganic or organic acid. The salt means a salt commonly used in the pharmaceutical industry to which the present invention belongs, and may be specifically a salt derived from one or more acids selected from hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, oxalic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, or toluenesulfonic acid.
[0041] The compound of the present invention may also be in the form of a solvate. The term "solvate" refers to a complex or aggregate formed by one or more solute molecules, i.e., the compound shown in Chemical Formula 1 or a pharma- ceutically acceptable salt thereof; and one or more solvent molecules. The solvate may be a complex or aggregate formed with various solvent molecules, such as, for example, water, methanol, ethanol, isopropanol, or acetic acid.
[0042] The compounds of the present invention may also be in the form of their stereoisomers. The stereoisomers include all stereoisomers, such as enantiomers and diastereomers. The compounds may be in stereoisomerically pure form or a mixture of one or more stereoisomers, such as a racemic mixture. Separation of a particular stereoisomer may be performed by any of the conventional methods known in the art. Some examples of the compounds of the present invention may have a greater anti-cancer effect of a particular stereoisomer compared to the racemic mixture. In this case, the dosage may be reduced by using a particular stereoisomer. Thus, cancer can be effectively treated by isolating a particular stereoisomer, such as an enantiomer or a partial structural isomer, that has a greater killing effect on cancer cells.
[0043] According to another aspect of the present invention, there is provided a pharmaceutical composition for treating or preventing cancer or hyperproliferative disease, comprising, as an active ingredient, a compound of the present invention or a pharma- ceutical salt thereof, and a pharma- ceutical acceptable carrier. The cancer or hyperproliferative disease may be a disease caused by ALK overexpression or ALK mutation, or a disease caused by EGFR mutation.
[0044] The pharmaceutical composition of the present invention uses the above-mentioned Chemical formula 1 or a salt thereof as an active ingredient, so that the description of the matters common to the contents described above will be omitted in this specification to avoid excessive duplication.
[0045] The pharmaceutical compositions of the present invention can be formulated according to conventional methods and manufactured into a variety of oral dosage forms such as tablets, pills, powders, capsules, syrups, emulsions, microemulsions, etc., or parenteral dosage forms such as intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal injection, and direct injection into tissue.
[0046] In the present invention, the term "pharmaceutical acceptable carrier" refers to a substance, usually an inactive substance, used in combination with an active ingredient to facilitate application of the active ingredient. The carrier may include, for example, one or more selected from fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, flavoring agents, thickeners, coloring agents, emulsifiers, suspending agents, stabilizers, pH adjusters, and isotonicity agents.
[0047] Examples of the carrier used in the present invention include cellulose, calcium silicate, lactose, dextrose, cornstarch, sucrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, emulsifiers, suspending agents, diluents, etc. When the pharmaceutical composition of the present invention is prepared in the form of an injection, the carrier may be water, saline, an aqueous glucose solution, an aqueous analogue sugar solution, alcohol, glycol, oil, fatty acid, fatty acid ester, glyceride, surfactant, suspending agent, emulsifying agent, etc.
[0048] According to another aspect of the present invention, there is provided a method for preventing or treating the aforementioned diseases by administering a compound of the present invention, or a pharma- ceutically acceptable salt thereof, to an individual in need thereof.
[0049] The dosage of the pharmaceutical composition of the invention may vary depending on a variety of factors, such as the condition of the patient, the route of administration, the judgment of the attending physician, etc. Effective dosages may be extrapolated from dose-response curves derived from in vitro or animal model tests. The proportion and concentration of the compound of the invention present in the administered composition may be determined depending on the chemical properties, the route of administration, the therapeutic dose, etc.
[0050] The dosage of the pharmaceutical composition of the present invention may be, for example, 0.0001 mg / kg (body weight) to 100 mg / kg (body weight) based on the compound of formula 1.
[0051] The pharmaceutical composition of the present invention may further comprise one or more selected from an immunomodulatory agent, a chemo-cancer agent, and an immuno-cancer agent.
[0052] The cytokine suitable for use as the immunomodulatory agent may be selected from, but is not limited to, interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), or granulocyte, macrophage colony stimulating factor (GM-CSF).
[0053] The anticancer chemotherapy agent may be, but is not limited to, gemcitabine, cytarabine, carboplatin, cisplatin, crizotinib, cyclophosphamide, docetaxel, doxorubicin, etoposide, 5-fluorouracil, irinotecan, methotrexate, paclitaxel, topotecan, trabectedin, vincristine, or vinblastine.
[0054] The immune anticancer agent may be an immune checkpoint inhibitor against any one selected from the group consisting of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), PD-1 (Programmed cell death protein 1), LAG-3 (Lymphocyte Activation Gene-3), TIM-3 (T-cell Immunoglobulin and Mucin-domain containing-3), TIGIT (T-cell Immunoreptor with IG and ITIM domain), or VISTA (V-domain Ig Suppressor of T cell Activation), but is not limited thereto. EXAMPLES
[0055] The present invention will be described in more detail below with reference to examples. These examples are provided to more specifically explain the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not limited to these examples according to the gist of the present invention.
[0056] The compound of the present invention represented by Chemical Formula 1 can be prepared, for example, by the method represented by the following reaction scheme 1: [ka]
[0057] Step A-1: Synthesis of N-methyl-N-(2-nitrophenyl)methanesulfonamide [ka]
[0058] Dissolve 1-fluoro-2-nitrobenzene (1.0 equivalent) in acetonitrile, add potassium carbonate (2.0 equivalent) and N-methylmethanesulfonamide (1.4 equivalent) at room temperature, and stir at 80°C overnight. After the reaction is complete, cool to room temperature and filter. Evaporate the filtrate under reduced pressure to obtain the compound. Use it in the next reaction without separation.
[0059] Step A-2: Synthesis of N-(2-aminophenyl)-N-methylmethanesulfonamide [ka]
[0060] Dissolve N-methyl-N-(2-nitrophenyl)methanesulfonamide (1.0 equivalent) in methanol and ethyl acetate (1:1) and add 10% palladium on charcoal (0.2 equivalent). Stir under hydrogen for 2 hours. After the reaction is complete, filter through Celite. Evaporate the filtrate under reduced pressure. Solidify with ethyl ether and pentane. Filter to obtain the desired compound. Use it in the next reaction without any separation process.
[0061] Step A-3: Synthesis of N-(2-((2,5-dichloropyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide [ka]
[0062] Dissolve N-(2-aminophenyl)-N-methylmethanesulfonamide (1.0 equivalent) in isopropyl alcohol, add 2,4,5-trichloropyrimidine (1.1 equivalent) and N,N-diisopropylethylamine (2.5 equivalent) at room temperature. Stir at 80°C overnight. After the reaction is complete, evaporate the filtrate under reduced pressure and extract with water and dichloromethane. Wash the organic layer with 2N hydrochloric acid. Evaporate the organic layer under reduced pressure to obtain the target compound. Use it in the next reaction without separation.
[0063] Step B-1: Synthesis of tert-butyl 4-(5-fluoro-2-methyl-4-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate [ka]
[0064] Dissolve 1-bromo-5-fluoro-2-methyl-4-nitrobenzene (1.0 eq.) in 1,2-dimethoxyethane and water (10:1). Add tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.0 eq.), potassium carbonate (3.0 eq.), and (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride (0.04 eq.) at room temperature. Reflux under nitrogen. After the reaction is complete, extract with water and ethyl acetate. Collect the organic layer, evaporate under reduced pressure, and use column chromatography to obtain the target compound (hexane:ethyl acetate=3:1).
[0065] Step B-2: Synthesis of tert-butyl 4-(5-isopropoxy-2-methyl-4-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate [ka]
[0066] Tert-butyl 4-(5-fluoro-2-methyl-4-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate (1.0 equivalent) is dissolved in isopropyl alcohol, and cesium carbonate (3.0 equivalent) is added at room temperature. Then, the mixture is stirred at 60°C overnight. After the reaction is completed, the mixture is extracted with water and ethyl acetate. The organic layer is collected and evaporated under reduced pressure, and the target compound is obtained using column chromatography (hexane:ethyl acetate=4:1).
[0067] Step B-3: Synthesis of 4-(5-isopropoxy-2-methyl-4-nitrophenyl)-1,2,3,6-tetrahydropyridine [ka]
[0068] Tert-butyl 4-(5-isopropoxy-2-methyl-4-nitrophenyl)-3,6-dihydropyridine-1(2H)-carboxylate (1.0 equivalent) is dissolved in dichloromethane, and trifluoroacetic acid (1.0 equivalent) is added at 0°C. After the reaction is completed, the mixture is neutralized with 1N sodium hydroxide and extracted with water and dichloromethane. The organic layer is collected and evaporated under reduced pressure, and used in the next reaction without separation.
[0069] Step B-4: Synthesis of 4-(5-isopropoxy-2-methyl-4-nitrophenyl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridine [ka]
[0070] Dissolve 4-(5-isopropoxy-2-methyl-4-nitrophenyl)-1,2,3,6-tetrahydropyridine (1.0 eq.) in toluene, add tetrahydro-4H-pyran-4-one (1.2 eq.), triethylamine (2.58 eq.), acetic acid (1.53 eq.) and sodium triacetoxyborohydride (0.83 eq. x 3) at room temperature. Stir overnight at room temperature. After completion of the reaction, extract with water and ethyl acetate. Collect the organic layer, evaporate under reduced pressure and use it for the next reaction without separation.
[0071] Example 1: Preparation of N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide [ka] Step B-5: Synthesis of 2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)aniline [ka] Dissolve 4-(5-isopropoxy-2-methyl-4-nitrophenyl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridine (1.0 eq.) in 1,4-dioxane and water (3:1), add zinc (10.0 eq.) and ammonium chloride (10.0 eq.) at 0°C. Stir overnight at room temperature. After the reaction is complete, extract with water and ethyl acetate. The organic layer is collected and evaporated under reduced pressure, and used in the next reaction without separation.
[0072] Step C-1: Synthesis of the final compound Dissolve the pyrimidine derivative (1.0 equivalent) in isopropyl alcohol, add the aniline derivative (1.0 equivalent) and methanesulfanilic acid (1.3 equivalent) at room temperature. Stir at 80°C overnight. After the reaction is complete, remove the solvent by evaporation under reduced pressure, and extract with a mixture of water and dichloromethane. Evaporate the organic layer under reduced pressure, and perform column chromatography to obtain the target compound (methyl alcohol: dichloromethane = 10:1). Yield: 15.6%; Pale yellow solid; 1H NMR(400 MHz, DMSO-d6) δ 8.37(s, 1H), 8.18 - 8.12(m, 2H), 7.83(s, 1H), 7.64 - 7.55(m, 2H), 7.30(td, J = 8.4, 7.9, 1.5 Hz, 1H), 7.20(td, J = 7.6, 1.6 Hz, 1H), 6.67(s, 1H), 5.51 - 5.46(m, 1H), 4.53(hept, J = 6.1 Hz, 1H), 3.87(dd, J = 10.9, 4.2Hz, 2H), 3.26 - 3.23(m, 3H), 3.18 - 3.10(m, 5H), 3.05(s, 3H), 2.65(t, J = 5.5 Hz, 2H), 2.24(m, 2H), 2.03(s, 3H), 1.72(m, 2H), 1.42(qd, J = 12.2, 4.4 Hz, 2H), 1.29 - 1.12(m, 8H). MS: ESI m / z 641.2664 [M+H]+
[0073] Example 2: Preparation of N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide [ka]
[0074] The synthesis was carried out according to the method of Step C-1. Yield: 15.5%; Yellow solid; 1H NMR(500 MHz, DMSO-D6) δ 9.33(s, 1H), 8.64(s, 1H), 8.16(s, 1H), 7.88(d; J = 7.8 Hz, 1H), 7.69(s, 1H), 7.63(s, 1H), 7.41(dd; J = 7.4, 2.0 Hz, 1H), 7.29 - 7.19(m, 2H), 6.68(s, 1H), 5.50(d; J = 4.0 Hz, 1H), 4.56(p, J = 6.1 Hz, 1H), 3.95 - 3.87(m, 2H), 3.31 - 3.27(m, 2H), 3.17(d; J = 3.4 Hz, 2H), 2.92(s, 3H), 2.70(t, J = 5.5 Hz, 2H), 2.26(s, 2H), 1.98(s, 3H), 1.77(d; J = 13.0 Hz, 2H), 1.48(tt, J = 12.0, 6.1 Hz, 2H), 1.24(d; J = 6.0 Hz, 6H). MS: ESI m / z 626.2433 [M]+
[0075] Example 3: Preparation of N-(2-((5-chloro-2-(2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylcyclopropanesulfonamide [ka] The synthesis was carried out according to the method of Step C-1. Yield: 27.2%; Yellow solid; 1H NMR(500 MHz, DMSO-D6) δ 8.38(s, 1H), 8.19(s, 1H), 8.17(s, 1H), 7.87(s, 1H), 7.70 - 7.67(m, 1H), 7.66(d, J = 1.8 Hz, 1H), 7.34(t, J = 7.6 Hz, 1H), 7.23(td, J = 7.7, 1.6 Hz, 1H), 6.72(s, 1H), 5.76(s, 1H), 5.53(d, J = 4.3 Hz, 1H), 4.56(hept, J = 6.1 Hz, 1H), 3.94 - 3.88(m, 2H), 3.32 - 3.27(m, 2H), 3.22(s, 3H), 3.17(q, J = 3.0 Hz, 2H), 2.84(td, J = 7.9, 4.0 Hz, 1H), 2.70(t, J = 5.5 Hz, 2H), 2.29(s, 2H), 2.08(d, J = 2.5 Hz, 3H), 1.80 - 1.73(m, 2H), 1.47(qd, J = 12.2, 4.3 Hz, 2H), 1.24(d, J = 6.0 Hz, 6H), 1.07 - 1.02(m, 2H), 0.87(s, 2H). MS: ESI m / z 666.2 [M]+
[0076] Example 4: Preparation of N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylpropane-2-sulfonamide [ka] The synthesis was carried out according to the method of Step C-1. Yield: 32.1%; Yellow solid; 1H NMR(500 MHz, DMSO-D6) δ 8.44(s, 1H), 8.18(s, 1H), 7.99(d, J = 8.1 Hz, 1H), 7.77(s, 1H), 7.63(s, 1H), 7.60(dd, J = 8.0, 1.5 Hz, 1H), 7.41 - 7.34(m, 1H), 7.29(t, J = 7.4 Hz, 1H), 6.69(s, 1H), 5.53 - 5.48(m, 1H), 4.56(hept, J = 6.1 Hz, 1H), 3.94 - 3.83(m, 2H), 3.53(p, J = 6.7 Hz, 1H), 3.29(dd, J = 11.8, 2.0 Hz, 2H), 3.19(s, 3H), 3.15(q, J = 3.0 Hz, 2H), 2.68(t, J = 5.5 Hz, 2H), 2.29 - 2.23(m, 2H), 2.01(s, 3H), 1.79 - 1.72(m, 2H), 1.47(qd, J = 12.3, 4.5 Hz, 2H), 1.28(d, J = 6.7 Hz, 6H), 1.24(d, J = 6.0 Hz, 6H). MS: ESI m / z 668.2 [M]+
[0077] Example 5: Preparation of N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-cyclopropylmethanesulfonamide [ka] The synthesis was carried out according to the method of Step C-1. Yield: 55.9%; Yellow solid; 1H NMR(500 MHz, DMSO-D6) δ 8.22(d, J = 8.1 Hz, 1H), 8.19(s, 1H), 8.07(s, 1H), 7.93(s, 1H), 7.67(dd, J = 7.9, 1.6 Hz, 1H), 7.64(s, 1H), 7.32(t, J = 7.6 Hz, 1H), 7.24(td, J = 7.6, 1.6 Hz, 1H), 6.72(s, 1H), 5.54(dt, J = 3.6, 1.9 Hz, 1H), 4.56(hept, J = 6.4 Hz, 1H), 3.95 - 3.88(m, 2H), 3.32 - 3.27(m, 2H), 3.24(dq, J = 5.5, 3.3, 2.7 Hz, 1H), 3.21(s, 3H), 3.17(q, J = 3.0 Hz, 2H), 2.70(t, J = 5.4 Hz, 2H), 2.29(d, J = 5.7 Hz, 2H), 2.09(d, J = 5.9 Hz, 3H), 1.80 - 1.73(m, 2H), 1.48(qd, J = 12.1, 4.4 Hz, 2H), 1.23(dd, J = 6.0, 4.3 Hz, 6H), 0.94(td, J = 8.1, 7.5, 4.4 Hz, 2H), 0.56 - 0.47(m, 1H), 0.15(dp, J = 8.7, 4.6 Hz, 1H). MS: ESI m / z 666.2 [M]+
[0078] Example 6: Preparation of N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-isopropylmethanesulfonamide [ka] The synthesis was carried out according to the method of Step C-1. Yield: 56.1%; Yellow solid; 1H NMR(500 MHz, DMSO-D6) δ 8.21(d, J = 3.6 Hz, 2H), 8.16(s, 1H), 7.90(s, 1H), 7.69(s, 1H), 7.49(dd, J = 7.9, 1.6 Hz, 1H), 7.45 - 7.38(m, 1H), 7.25(td, J = 7.7, 1.5 Hz, 1H), 6.72(s, 1H), 5.53(d, J = 3.8 Hz, 1H), 4.56(hept, J = 6.5, 6.0 Hz, 1H), 4.43(p, J = 6.7 Hz, 1H), 3.91(dd, J = 10.4, 4.1 Hz, 2H), 3.33 - 3.27(m, 3H), 3.17(d, J = 3.2 Hz, 2H), 3.15(s, 3H), 2.70(t, J = 5.5 Hz, 2H), 2.29(s, 2H), 2.09(s, 2H), 2.05(s, 3H), 1.77(d, J = 12.2 Hz, 2H), 1.47(qd, J = 12.1, 4.4 Hz, 2H), 1.24(t, J = 6.3 Hz, 6H), 1.18(d, J = 6.6 Hz, 3H), 0.90(d, J = 6.7 Hz, 3H). MS: ESI m / z 668.2 [M]+
[0079] Example 7: Preparation of N-(2-((5-chloro-2-((5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-(2,2,2-trifluoroethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide [ka] The synthesis was carried out according to the method of Step C-1. Yield: 35.7%; Yellow solid; 1H NMR(500 MHz, DMSO-D6) δ 8.38(s, 1H), 8.17(s, 1H), 8.15(d, J = 4.5 Hz, 2H), 7.61(dd, J = 7.9, 1.6 Hz, 1H), 7.51(s, 1H), 7.27(td, J = 7.8, 1.6 Hz, 1H), 7.21(td, J = 7.6, 1.7 Hz, 1H), 6.91(s, 1H), 5.57(dt, J = 3.6, 1.8 Hz, 1H), 4.69(q, J = 8.9 Hz, 2H), 3.95 - 3.88(m, 2H), 3.30(dd, J = 11.7, 2.0 Hz, 2H), 3.18(d, J = 2.6 Hz, 5H), 3.09(s, 3H), 2.71(t, J = 5.5 Hz, 2H), 2.31(dq, J = 5.9, 3.0 Hz, 2H), 2.12(s, 3H), 1.81 - 1.74(m, 2H), 1.48(qd, J = 12.1, 4.4 Hz, 2H), 1.32 - 1.21(m, 1H). MS: ESI m / z 680.2 [M]+
[0080] Example 8: Preparation of N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylsulfonamide [ka] The synthesis was carried out according to the method of Step C-1. Yield: 45.2%; Yellow solid; 1H NMR (500 MHz, DMSO-D6)1H NMR (500 MHz, Chloroform-d) δ 9.21 (s, 1H), 8.52 (s, 1H), 8.43 (s, 1H), 7.43 (dd, J = 7.5, 1.6 Hz, 1H), 7.39 (dd, J = 7.4, 1.5 Hz, 1H), 7.14 (s, 1H), 7.03 (td, J = 7.4, 1.5 Hz, 1H), 6.93 (s, 2H), 6.87 (s, 1H), 6.80 (td, J = 7.5, 1.5 Hz, 1H), 6.06 (tt, J = 6.2, 1.0 Hz, 1H), 4.63 (dt, J = 13.5, 6.6 Hz, 1H), 3.70 (dt, J = 12.4, 7.1 Hz, 2H), 3.60 (dt, J = 12.6, 7.1 Hz, 2H), 3.43 (s, 3H), 3.30 (dt, J = 6.2, 1.0 Hz, 2H), 2.94 (p, J = 6.9 Hz, 1H), 2.84 (td, J = 7.1, 0.9 Hz, 2H), 2.71 (tt, J = 6.9, 0.9 Hz, 2H), 2.41 (s, 3H), 1.90 - 1.71 (m, 4H), 1.33 (d, J = 6.9 Hz, 6H). MS: ESI m / z 641.3 [M]+
[0081] Experimental Example 1: Measurement of kinase inhibitory activity The inhibitory activity against ALK, ALK mutation (ALK (G1202R)), and EGFR mutation (ALK (L1196M)) kinase was measured for the compounds of Examples 1 to 8, and the results are shown in Table 1 below. The kinase inhibitory activity was measured using IC 50 The values were calculated and shown. Crizotinib (APG-2449) was used as a control drug. 1. Each kinase was dissolved in 8 mM MOPS, pH 7.0, 0.2 mM EDTA, 250 μM KKKGQEEEYVFIE, 1 mM sodium orthovanadate, 5 mM sodium-6-glycerophosphate, 10 mM magnesium acetate, [ 33 P]-ATP. 2. The compound to be evaluated (DMSO solution) and Mg / ATP were added to initiate the reaction. 3. After about 40 minutes at room temperature, 10 uL of 0.5% phosphoric acid was added to terminate the reaction. 4. The reaction solution was divided into 10 μL portions using 0.5% PBS and spotted onto a P30 filtermat. 5. Wash four times with 0.425% phosphoric acid for about 4 minutes. Wash once with methanol, then dry and analyze by scintillation counting to obtain IC 50 The values were measured.
[0082] [Table 1]
[0083] As shown in the experimental results in Table 1, the compounds prepared according to the examples of the present invention showed similar inhibitory activity against wild-type ALK kinase, but showed significantly superior activity against ALK point mutant kinase, compared to APG-2449. <APG-2449 Chemical Structure> [ka]
[0084] Experimental Example 2: Measurement of the effect of inhibiting cancer cell growth For the compounds of Examples 3, 7, and 8, the growth inhibitory effects on ALK mutant cancer cell lines were measured. Using H3122 (EML4-ALK v1) and H2228 (EML4-ALK v3) as ALK mutant cell lines, the measurement of anti-cancer efficacy activity was carried out by the following method.
[0085] Gene construction: Wild type and mutant EGFR were purchased from Addgene. All constructions were finally completed as viral particles for infection as a retroviral vector.
[0086] <Confirmation of changes in Cellular kinase activity (Western blotting)> Each cell line was treated with each compound of Examples 3, 7, and 8 in a concentration-dependent manner, and cells were obtained after 5 hours. Cell lysates were made using EBC lysis buffer (50 mM Tris-HCl [pH 8.0], 120 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 0.3 mM phenylmethylsulfonylfluoride, 0.2 mM sodium orthovanadate, 0.5% NP-40, and 5 U / mL aprotinin).
[0087] <Verification of anti-cancer effect by MTT assay> 2 X 10 5 cells were seeded in a 96-well plate. After 24 hours, each compound of Examples 3, 7, and 8 was treated in a dose-dependent manner, then incubated for 72 hours, 15 uL of MTT reagent was reacted for 4 hours, 100 uL of 10% SDS was added and then incubated for 24 hours. The change in the final OD was read at 595 nm. The analysis of the MTT results was used to measure the IC 50 value.
[0088] The IC value was determined by the concentration at which each compound inhibited cell growth by 50%. 50 The values were calculated, and the results are shown in the following Table 2. APG-2449 was used as a control drug.
[0089] [Table 2]
[0090] As shown in the experimental results in Table 2, it was confirmed that the compounds prepared according to the examples of the present invention exhibited significant cancer cell growth inhibitory activity against the mutant-expressing cancer cell lines compared to APG-2449.
Claims
1. A compound represented by the following formula 1 or a pharma- ceutically acceptable salt thereof; [Formula 1] In the above Chemical Formula 1, R 1 is an alkyl group with C1 to C4 residues, a cycloalkyl group with C3 to C6 residues, and CF 3 , or -NR 8 R 9 where R 8 and R 9 are each independently hydrogen or a C1-C4 alkyl group, R 2 is hydrogen, a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or -NR 10 R 11 where R 10 and R 11 are each independently hydrogen or a C1-C4 alkyl group, R 3 is hydrogen or a halogen radical, R 4 are hydrogen, halogens, OH, CN, and CF 3 , C1-C4 alkoxy, or C1-C4 alkyl group; R 5 is a C1-C4 alkoxy group, a C3-C6 cycloalkoxy group, and CF 3 a C1-C4 alkoxy group, a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or a C3-C6 heterocycloalkyl group, each of which is substituted with, wherein the heterocycloalkyl group contains from 1 to 3 heteroatoms selected from N, O, and S; R 6 is hydrogen, a halogen group, a C1-C4 alkyl group, or a C3-C6 cycloalkyl group, R 1a , R 1b , R 2a and R 2b are each independently hydrogen, a C1-C4 alkyl group, or a halogen; R 7is hydrogen, a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or a C3-C8 heterocycloalkyl group, where the heterocycle contains 1 to 3 heteroatoms selected from N, O, and S.
2. R 1 is a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or -NR 8 R 9 where R 8 and R 9 are each independently hydrogen or a C1-C4 alkyl group, R 2 is hydrogen, a C1-C4 alkyl group, or a C3-C6 cycloalkyl group, R 3 is hydrogen or a halogen radical, R 4 is hydrogen, halogen, OH, CN, or CF 3 and R 5 is a C1-C4 alkoxy group, a C3-C6 cycloalkoxy group, or CF 3 is a C1-C4 alkoxy group substituted with R 6 is hydrogen, a C1-C4 alkyl group, or a C3-C6 cycloalkyl group, R 1a , R 1b , R 2a and R 2b is hydrogen, R 7 is a C3-C6 cycloalkyl group or a C3-C8 heterocycloalkyl group, wherein the heterocycle contains 1 to 3 heteroatoms selected from N, O and S. The compound according to claim 1, or a pharma- ceutically acceptable salt thereof.
3. The compound of formula 1 is selected from the group consisting of the following compounds: N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylcyclopropanesulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylpropane-2-sulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-cyclopropylmethanesulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-isopropylmethanesulfonamide, N-(2-((5-chloro-2-((5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-(2,2,2-trifluoroethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide, N-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylsulfonamide.
4. 1. A pharmaceutical composition for treating cancer or a hyperproliferative disease, comprising as an active ingredient the compound represented by formula 1 of claim 1 or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.
5. The pharmaceutical composition for treating cancer or a hyperproliferative disease according to claim 4, wherein the cancer or hyperproliferative disease is caused by ALK overexpression, ALK mutation, or EGFR mutation.
6. 6. The pharmaceutical composition for treating cancer or hyperproliferative disease according to claim 5, wherein the cancer is liver cancer, gastric cancer, pancreatic cancer, colon cancer, leukemia, myeloproliferative / myelodysplastic disease, dermatofibrosarcoma, breast cancer, lung cancer, thyroid cancer, prostate cancer, ovarian cancer, brain tumor, osteosarcoma, or head and neck cancer.
7. The pharmaceutical composition for treating cancer or a hyperproliferative disease according to claim 4, wherein the cancer is non-small cell lung cancer with ALK overexpression or ALK mutation, or EGFR-mutated non-small cell lung cancer.
8. 5. The pharmaceutical composition for treating cancer or a hyperproliferative disease according to claim 4, further comprising one or more selected from an immunomodulatory agent, a chemical anti-cancer agent, and an immune anti-cancer agent.
